Jeanne Link, M.S., Ph.D.

  • Professor of Diagnostic Radiology, School of Medicine
  • Director, Center for Radiochemistry Research, School of Medicine

Biography

Jeanne Link is the Director for the Center for Radiochemistry Research at Oregon Health & Science University and has worked on development of new radiopharmaceuticals for three decades. She received her BS from the University of California at Davis in Biological Sciences, a MS in Radiation Ecology and PhD in Analytical and Radiochemistry from University of Washington. She led PET radiochemistry operations at the University of Washington for 20 years prior to moving to OHSU in 2014.

Dr. Link’s scientific goals include molecular imaging using gamma emitting radiation, which is the most sensitive noninvasive method available to evaluate most biochemical pathways in vivo. When a radiolabeled chemical or quantitative biochemical is injected and used with positron emission tomography (PET) imaging, a temporal and spatial distribution of the compound throughout the body is obtained. The Center for Radiochemistry Research makes radiolabeled compounds that target specific pathways in the body, such as parts of signaling systems, including the transmitters and receptors and enzymes in those pathways. Other compounds can show the spatial distribution of a drug throughout the body and there are a myriad of other potential targets. The limit of the technique is how carefully we ask the question about a disease. Dr. Link's work focuses on translating what has been learned in cellular work and animal studies to further research in animal models and human imaging studies. This leads to a better understanding of the mechanisms, extent and phenotype of diseases. This work improves understanding of disease and drugs in vivo to select appropriate treatment for an individual therapy, thereby improving outcome.

Education

  • B.S., 1974, University of California Davis
  • M.S., 1982, University of Washington
  • Ph.D., 1998, University of Washington

Memberships and associations

  • American Chemical Society
  • Society of Nuclear Medicine
  • International Society of Radiopharmaceutical Sciences
  • American Society of Nuclear Cardiology

Areas of interest

  • Partnering with scientists to understand the spatial and functional status of biological systems in vivo
  • Working with scientists to detect the extent and amount of disease in vivo
  • Collaborating with radiochemistry experts to develop image analysis techniques
  • Working with scientists to analyze response to radiation therapies
  • Development of new radiochemistry methods and radiopharmaceuticals
  • Enhancing radiochemistry by developing and simplifying automated radiosynthesis
  • Advancing radiochemistry by developing more robust and streamlined techniques

Publications

Selected publications

  • Link JM, Krohn KA, Eary JF, Kishore R, Lewellen TK, Johnson MW, Badger CC, Richter KY, Nelp WB. 89Zr for antibody labeling and positron emission tomography. J. Label Comp Radiopharm 23: 1297-1298, 1986.
  • Link JM, Synovec RE. Whole Column Radioactivity Detection: Simultaneous Separation and Enhanced Detectability. Anal Chem. 71(14):2700-2707, 1999. PMID: 10424163
  • Link JM, Stratton JR, Levy WC, Poole JE, Shoner SC, Stuetzle W, Caldwell JC. PET Measures of Pre- and Post-synpatic Cardiac Beta Adrenergic Function. Nucl. Med. & Biol. 30(8):795-803, 2003. PMID: 14698782
  • Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat, JD.  Imaging p-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol. Ther. 77: 503-514, 2005, PMID: 15961982
  • Mann GN, Link JM, Pickett CA, Byrd DR, Kinahan PE, Krohn KA, Mankoff DA. [C-11]meta-hydroxyephedrine and [F-18] fluorodeoxyglucose positron emission tomography improves clinical decision making in suspected pheochromocytoma. Annals Surg Oncol 13: 187 – 197, 2006. PMID: 16418883
  • Linden HM, Stekhova S, Link JM, Gralow JR, Livingston RB, Ellis GK, Peterson LM. Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Quantitative fluoroestradiol (FES) PET imaging predicts response to endocrine treatment. J Clin Oncol, 24:2793:2799, 2006. PMID: 16682724
  • Link JM, Caldwell JH. Diagnostic and prognostic imaging of the cardiac sympathetic nervous system. Nat Clin Pract Cardiovasc Med. 5 Suppl 2:S79-86, 2008. PMID: 18641611
  • Eyal S, Ke B, Muzi M, Link JM, Mankoff DA, Collier AC, Unadkat JD. Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther 2010 May; 87(5):579-85. Epub 2010 Mar 24. PMID: 20336065
  • Eary JE, Link JM, Muzi M, Conrad EU, Mankoff DA, White JK, Krohn KA. Multiagent PET for Risk Characterization in Sarcoma. J. Nucl Med. 2011 Apr; 52(4):541-546. PMID: 21421714
  • Deo Anand K., Borson Soo, Jeanne M. Link, Karen Domino, Janet F. Eary, Ban Ke, Todd L. Richards, David A. Mankoff, Satoshi Minoshima, Finbarr O’Sullivan, Sara Eyal, Peng Hsiao, Ken Maravilla, Jashvant D. Unadkat.   Activity of P-glycoprotein, a b-amyloid Transporter at the Blood-Brain Barrier, is Compromised in  Patients with Mild Alzheimer’s Disease. J. Nucl Med & Molec Imag.   May 19; 55 (7):1106-111, 2014. PMID: 24842892

Publications

  • {{ pub.journalAssociation.journal.names[0].value }}